Crossmark

Molecular characterization and improved risk stratification of myelodysplastic syndromes with bone marrow fibrosis through integration of TP53 and MPL mutations

Crossref DOI link: https://doi.org/10.1007/s12672-026-04962-w

Published Online: 2026-04-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhao, Youshan

Zhao, Sida

Wang, Roujia

Guo, Juan

Chang, Chunkang
Funding

Funding for this research was provided by:

Clinical Research Plan of SHDC (SHDC2024CRI057)

Shanghai Science and Technology Committee (21Y31920400)
License Information

Text and Data Mining valid from 2026-04-12

Version of Record valid from 2026-05-25
More Information

Article History

Received: 11 November 2025

Accepted: 3 April 2026

First Online: 12 April 2026

Declarations

:

: The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Shanghai Sixth People’s Hospital (protocol code 2021-033, date of approval 25 February 2021).

: Informed consent was obtained from all individual participants or their legal guardians included in the study.

: All authors agree to publish.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below